{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:29:40Z","timestamp":1792794580213,"version":"4.5.0"},"reference-count":112,"publisher":"American Diabetes Association","issue":"Supplement_1","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:p>The American Diabetes Association (ADA) \u201cStandards of Care in Diabetes\u201d includes the ADA\u2019s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA\u2019s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org\/SOC.<\/jats:p>","DOI":"10.2337\/dc24-s012","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T06:57:13Z","timestamp":1702277833000},"page":"S231-S243","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":202,"title":["12. Retinopathy, Neuropathy, and Foot Care:\n                    <i>Standards of Care in Diabetes\u20142024<\/i>"],"prefix":"10.2337","volume":"47","author":[{"name":"American Diabetes Association Professional Practice Committee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuha A.","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Aleppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveendhara R.","family":"Bannuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Bruemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy S.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laya","family":"Ekhlaspour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Giurini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa E.","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Matfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Pilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Prahalad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa R.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Jeffrie","family":"Seley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Gabbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"2024020516050886700_B1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"2024020516050886700_B3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"key":"2024020516050886700_B4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/ajkd.1998.v31.pm9631838","article-title":"Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM","volume":"31","author":"Estacio","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2024020516050886700_B5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00125-019-4959-1","article-title":"New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism","volume":"62","author":"Eid","year":"2019","journal-title":"Diabetologia"},{"key":"2024020516050886700_B7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2024020516050886700_B8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"2024020516050886700_B9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jamaophthalmol.2015.4606","article-title":"Effects of prior intensive insulin therapy and risk factors on patient-reported visual function outcomes in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) cohort","volume":"134","author":"Gubitosi-Klug","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2024020516050886700_B10","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1409463","article-title":"Intensive diabetes therapy and ocular surgery in type 1 diabetes","volume":"372","author":"Aiello","year":"2015","journal-title":"N Engl J Med"},{"key":"2024020516050886700_B11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.0686","article-title":"Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood","volume":"317","author":"Dabelea","year":"2017","journal-title":"JAMA"},{"key":"2024020516050886700_B13","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc10-2308","article-title":"Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy","volume":"34","author":"Agardh","year":"2011","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B14","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1612836","article-title":"Frequency of evidence-based screening for retinopathy in type 1 diabetes","volume":"376","author":"Nathan","year":"2017","journal-title":"N Engl J Med"},{"key":"2024020516050886700_B15","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.ophtha.2016.01.043","article-title":"Identification of diabetic retinopathy and ungradable image rate with ultrawide field imaging in a national teleophthalmology program","volume":"123","author":"Silva","year":"2016","journal-title":"Ophthalmology"},{"key":"2024020516050886700_B16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archophthalmol.2010.319","article-title":"Screening for presence or absence of diabetic retinopathy: a meta-analysis","volume":"129","author":"Bragge","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"2024020516050886700_B17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaophthalmol.2015.5083","article-title":"Evaluation of automated teleretinal screening program for diabetic retinopathy","volume":"134","author":"Walton","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2024020516050886700_B18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2017.0204","article-title":"Implementation and evaluation of a large-scale teleretinal diabetic retinopathy screening program in the Los Angeles County Department of Health Services","volume":"177","author":"Daskivich","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2024020516050886700_B19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1932296816629983","article-title":"The evolution of teleophthalmology programs in the United Kingdom: beyond diabetic retinopathy screening","volume":"10","author":"Sim","year":"2016","journal-title":"J Diabetes Sci Technol"},{"key":"2024020516050886700_B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41746-018-0040-6","article-title":"Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices","volume":"1","author":"Abr\u00e0moff","year":"2018","journal-title":"NPJ Digit Med"},{"key":"2024020516050886700_B21","unstructured":"U.S. Food and Drug Administration\n          . K200667 - 510(k) Premarket notification. 2020. Accessed 8 September 2023. Available from https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K200667"},{"key":"2024020516050886700_B22","unstructured":"U.S. Food and Drug Administration\n          . FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems. 2018. Accessed 8 September 2023. Available from https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-artificial-intelligence-based-device-detect-certain-diabetes-related-eye"},{"key":"2024020516050886700_B23","unstructured":"U.S. Food and Drug Administration\n          . K221183 - 510(k) Premarket notification. 2022. Accessed 8 September 2023. Available from https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K221183"},{"key":"2024020516050886700_B24","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.2337\/db07-1024","article-title":"A 20-year prospective study of childbearing and incidence of diabetes in young women, controlling for glycemia before conception: the Coronary Artery Risk Development in Young Adults (CARDIA) Study","volume":"56","author":"Gunderson","year":"2007","journal-title":"Diabetes"},{"key":"2024020516050886700_B25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaophthalmol.2022.0050","article-title":"Global estimates of diabetic retinopathy prevalence and progression in pregnant women with preexisting diabetes: a systematic review and meta-analysis","volume":"140","author":"Widyaputri","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"2024020516050886700_B26","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/diacare.23.8.1084","article-title":"Effect of pregnancy on microvascular complications in the diabetes control and complications trial","volume":"23","author":"Diabetes Control and Complications Trial Research Group","year":"2000","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy","volume":"81","author":"The Diabetic Retinopathy Study Research Group","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"2024020516050886700_B28","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study research group","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"2024020516050886700_B29","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"2024020516050886700_B30","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"2024020516050886700_B31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaophthalmol.2021.0606","article-title":"Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the Protocol W randomized clinical trial","volume":"139","author":"Maturi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"2024020516050886700_B32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"key":"2024020516050886700_B33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"2024020516050886700_B34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"2024020516050886700_B35","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"2024020516050886700_B36","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"2024020516050886700_B37","first-page":"287","article-title":"Effects of lipid-lowering agents on diabetic retinopathy: a meta-analysis and systematic review","volume":"11","author":"Shi","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"2024020516050886700_B38","unstructured":"Centers for Disease Control and Prevention\n          . National Diabetes Statistics Report: Coexisting Conditions and Complications, 2022. Accessed 7 November 2023. Available from https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/coexisting-conditions-complications.html"},{"key":"2024020516050886700_B39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2010.08.003","article-title":"Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study","volume":"118","author":"Mazhar","year":"2011","journal-title":"Ophthalmology"},{"key":"2024020516050886700_B40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11892-014-0528-7","article-title":"Glucose control and diabetic neuropathy: lessons from recent large clinical trials","volume":"14","author":"Ang","year":"2014","journal-title":"Curr Diab Rep"},{"key":"2024020516050886700_B41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"2024020516050886700_B43","doi-asserted-by":"crossref","first-page":"102241","DOI":"10.1016\/j.dsx.2021.102241","article-title":"Optimal glycaemic and blood pressure but not lipid targets are related to a lower prevalence of diabetic microvascular complications","volume":"15","author":"Bashir","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"2024020516050886700_B44","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-017-4253-z","article-title":"Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study","volume":"60","author":"Look AHEAD Research Group","year":"2017","journal-title":"Diabetologia"},{"key":"2024020516050886700_B45","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/oby.23246","article-title":"Dietary weight loss in people with severe obesity stabilizes neuropathy and improves symptomatology","volume":"29","author":"Callaghan","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"2024020516050886700_B46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11892-009-0069-7","article-title":"Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy","volume":"9","author":"Freeman","year":"2009","journal-title":"Curr Diab Rep"},{"key":"2024020516050886700_B48","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2337\/dc10-0125","article-title":"Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2012.10.028","article-title":"Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT\/EDIC study (Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications)","volume":"61","author":"Pop-Busui","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024020516050886700_B50","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jdiacomp.2014.02.013","article-title":"The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy","volume":"28","author":"Smith","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2024020516050886700_B51","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ana.410380607","article-title":"Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial","volume":"38","author":"Diabetes Control and Complications Trial (DCCT) Research Group","year":"1995","journal-title":"Ann Neurol"},{"key":"2024020516050886700_B52","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s001250050924","article-title":"The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)","volume":"41","author":"The Diabetes Control and Complications Trial Research Group","year":"1998","journal-title":"Diabetologia"},{"key":"2024020516050886700_B53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc09-1941","article-title":"Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study","volume":"33","author":"Albers","year":"2010","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B54","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","article-title":"Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study (DCCT\/EDIC)","volume":"119","author":"Pop-Busui","year":"2009","journal-title":"Circulation"},{"key":"2024020516050886700_B55","first-page":"CD007543","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy","volume":"6","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2024020516050886700_B56","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/dc13-0012","article-title":"Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) cohort","volume":"36","author":"Pop-Busui","year":"2013","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/dc20-1842","article-title":"Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD trial","volume":"44","author":"Tang","year":"2021","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B58","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc16-0081","article-title":"Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status","volume":"39","author":"Callaghan","year":"2016","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B59","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/dc17-2062","article-title":"Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark","volume":"41","author":"Andersen","year":"2018","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B60","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/acn3.51639","article-title":"Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes","volume":"9","author":"Afshinnia","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"2024020516050886700_B61","doi-asserted-by":"crossref","first-page":"534372","DOI":"10.3389\/fpubh.2020.534372","article-title":"Prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: estimates of the INTERPRET-DD study","volume":"8","author":"Lu","year":"2020","journal-title":"Front Public Health"},{"key":"2024020516050886700_B62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DMSO.S37415","article-title":"Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey","volume":"6","author":"Sadosky","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2024020516050886700_B63","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1212\/WNL.0000000000003882","article-title":"Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review","volume":"88","author":"Waldfogel","year":"2017","journal-title":"Neurology"},{"key":"2024020516050886700_B64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","article-title":"Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee","volume":"98","author":"Price","year":"2022","journal-title":"Neurology"},{"key":"2024020516050886700_B65","doi-asserted-by":"crossref","DOI":"10.2337\/db2022-01","volume-title":"Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy","author":"Pop-Busui","year":"2022"},{"key":"2024020516050886700_B66","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial","volume":"400","author":"Tesfaye","year":"2022","journal-title":"Lancet"},{"key":"2024020516050886700_B67","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpain.2006.06.005","article-title":"Symptom profiles differ in patients with neuropathic versus non-neuropathic pain","volume":"8","author":"Dworkin","year":"2007","journal-title":"J Pain"},{"key":"2024020516050886700_B68","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archneur.61.6.914","article-title":"Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy","volume":"61","author":"Barbano","year":"2004","journal-title":"Arch Neurol"},{"key":"2024020516050886700_B69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/jch.12258","article-title":"Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches","volume":"16","author":"Briasoulis","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2024020516050886700_B70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3949\/ccjm.77a.09118","article-title":"Preventing and treating orthostatic hypotension: as easy as A, B, C","volume":"77","author":"Figueroa","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"2024020516050886700_B71","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/HJH.0000000000002078","article-title":"Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension","volume":"37","author":"Jordan","year":"2019","journal-title":"J Hypertens"},{"key":"2024020516050886700_B72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","article-title":"Clinical guideline: management of gastroparesis","volume":"108","author":"Camilleri","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2024020516050886700_B73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/diaspect.20.4.231","article-title":"Nutritional management of gastroparesis in people with diabetes","volume":"20","author":"Parrish","year":"2007","journal-title":"Diabetes Spectr"},{"key":"2024020516050886700_B74","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2011.04.045","article-title":"Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis","volume":"141","author":"Parkman","year":"2011","journal-title":"Gastroenterology"},{"key":"2024020516050886700_B75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ajg.2013.453","article-title":"A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial","volume":"109","author":"Olausson","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2024020516050886700_B76","volume-title":"Therapy for Diabetes Mellitus and Related Disorders","author":"Umpierrez","year":"2014","edition":"6th ed."},{"key":"2024020516050886700_B77","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.cgh.2008.02.065","article-title":"A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis","volume":"6","author":"Sugumar","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024020516050886700_B78","first-page":"259","article-title":"Oral erythromycin and symptomatic relief of gastroparesis: a systematic review","volume":"98","author":"Maganti","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2024020516050886700_B79","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cgh.2010.05.020","article-title":"Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study","volume":"8","author":"McCallum","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024020516050886700_B80","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2337\/dc08-9021","article-title":"Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists","volume":"31","author":"Boulton","year":"2008","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B81","doi-asserted-by":"crossref","first-page":"e3266","DOI":"10.1002\/dmrr.3266","article-title":"Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update)","volume":"36","author":"Schaper","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"2024020516050886700_B82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diacare.22.1.157","article-title":"Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings","volume":"22","author":"Reiber","year":"1999","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B83","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2337\/diacare.23.5.606","article-title":"Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial","volume":"23","author":"Pham","year":"2000","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B84","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2015.10.003","article-title":"The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine","volume":"63","author":"Hingorani","year":"2016","journal-title":"J Vasc Surg"},{"key":"2024020516050886700_B85","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2024020516050886700_B86","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.2337\/diacare.26.12.3333","article-title":"Peripheral arterial disease in people with diabetes","volume":"26","author":"American Diabetes Association","year":"2003","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B87","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/aphw.12314","article-title":"Information about foot care provided to people with diabetes with or without their partners: impact on recommended foot care behavior","volume":"14","author":"Reaney","year":"2022","journal-title":"Appl Psychol Health Well-Being"},{"key":"2024020516050886700_B88","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/iwj.13450","article-title":"A collaborative approach in patient education for diabetes foot and wound care: a pragmatic randomised controlled trial","volume":"17","author":"Heng","year":"2020","journal-title":"Int Wound J"},{"key":"2024020516050886700_B89","doi-asserted-by":"crossref","first-page":"e3269","DOI":"10.1002\/dmrr.3269","article-title":"Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update)","volume":"36","author":"Bus","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"2024020516050886700_B90","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejvs.2020.03.053","article-title":"A systematic review of the impact of foot care education on self efficacy and self care in patients with diabetes","volume":"60","author":"Goodall","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2024020516050886700_B91","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s12020-018-1714-1","article-title":"People with diabetes do not learn and recall their diabetes foot education: a cohort study","volume":"62","author":"Yuncken","year":"2018","journal-title":"Endocrine"},{"key":"2024020516050886700_B92","doi-asserted-by":"crossref","first-page":"598","DOI":"10.12968\/jowc.2021.30.8.598","article-title":"People living with diabetes are unaware of their foot risk status or why they are referred to a multidisciplinary foot team","volume":"30","author":"Walton","year":"2021","journal-title":"J Wound Care"},{"key":"2024020516050886700_B93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/dmrr.2702","article-title":"Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: a systematic review","volume":"32","author":"Bus","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"2024020516050886700_B94","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2337\/dc11-0844","article-title":"The Charcot foot in diabetes","volume":"34","author":"Rogers","year":"2011","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B95","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/wound.2015.0635","article-title":"Challenges in the treatment of chronic wounds","volume":"4","author":"Frykberg","year":"2015","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"2024020516050886700_B96","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/wound.2022.0041","article-title":"Efficacy of topical wound oxygen therapy in healing chronic diabetic foot ulcers: systematic review and meta-analysis","volume":"12","author":"Carter","year":"2023","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"2024020516050886700_B97","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2337\/dc19-0476","article-title":"A multinational, multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen (TWO2) therapy in the treatment of chronic diabetic foot ulcers: the TWO2 study","volume":"43","author":"Frykberg","year":"2020","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B98","doi-asserted-by":"crossref","DOI":"10.2337\/db2022-02","volume-title":"New Evidence-Based Therapies for Complex Diabetic Foot Wounds","author":"Boulton","year":"2022"},{"key":"2024020516050886700_B99","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.26.6.1879","article-title":"Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial","volume":"26","author":"Sheehan","year":"2003","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/dc07-2196","article-title":"Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial","volume":"31","author":"Blume","year":"2008","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B101","doi-asserted-by":"crossref","first-page":"127S","DOI":"10.1097\/01.prs.0000222551.10793.51","article-title":"Vacuum-assisted closure: state of clinic art","volume":"117","author":"Argenta","year":"2006","journal-title":"Plast Reconstr Surg"},{"key":"2024020516050886700_B102","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc09-1754","article-title":"Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes","volume":"33","author":"L\u00f6ndahl","year":"2010","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B103","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2337\/dc17-0654","article-title":"Hyperbaric oxygen therapy in the treatment of ischemic lower- extremity ulcers in patients with diabetes: results of the DAMO2CLES multicenter randomized clinical trial","volume":"41","author":"Santema","year":"2018","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B104","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2337\/dc15-2001","article-title":"Hyperbaric oxygen therapy does not reduce indications for amputation in patients with diabetes with nonhealing ulcers of the lower limb: a prospective, double-blind, randomized controlled clinical trial","volume":"39","author":"Fedorko","year":"2016","journal-title":"Diabetes Care"},{"key":"2024020516050886700_B105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/wrr.12776","article-title":"Hyperbaric oxygen therapy for nonischemic diabetic ulcers: a systematic review","volume":"28","author":"Lalieu","year":"2020","journal-title":"Wound Repair Regen"},{"key":"2024020516050886700_B106","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.12968\/jowc.2018.27.Sup9.S30","article-title":"Continuous diffusion of oxygen improves diabetic foot ulcer healing when compared with a placebo control: a randomised, double-blind, multicentre study","volume":"27","author":"Niederauer","year":"2018","journal-title":"J Wound Care"},{"key":"2024020516050886700_B107","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.12968\/jowc.2021.30.Sup5.S7","article-title":"Topical oxygen therapy in the treatment of diabetic foot ulcers: a multicentre, open, randomised controlled clinical trial","volume":"30","author":"Serena","year":"2021","journal-title":"J Wound Care"},{"key":"2024020516050886700_B108","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/iwj.13830","article-title":"Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: an updated systematic review and meta-analysis","volume":"19","author":"Sun","year":"2022","journal-title":"Int Wound J"},{"key":"2024020516050886700_B109","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/medicina57090917","article-title":"Topical wound oxygen therapy in the treatment of chronic diabetic foot ulcers","volume":"57","author":"Frykberg","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2024020516050886700_B110","first-page":"100028","article-title":"Topical oxygen therapy for healing diabetic foot ulcers: a systematic review and meta-analysis of randomised control trials","volume":"3","author":"Sethi","year":"2022","journal-title":"Health Sci Rep"},{"key":"2024020516050886700_B111","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/dmrr.2701","article-title":"Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review","volume":"32","author":"van Netten","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"2024020516050886700_B112","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.2337\/dc22-1111","article-title":"The at-risk diabetic foot: time to focus on prevention","volume":"45","author":"Frykberg","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/Supplement_1\/S231\/746951\/dc24s012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/Supplement_1\/S231\/746951\/dc24s012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:06:25Z","timestamp":1707131185000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/Supplement_1\/S231\/153941\/12-Retinopathy-Neuropathy-and-Foot-Care-Standards"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":112,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2023,12,11]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc24-s012","relation":{},"ISSN":["0149-5992"],"issn-type":[{"value":"0149-5992","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,11]]}}}